Caveolin-1: a critical regulator of pulmonary vascular architecture and nitric oxide bioavailability in pulmonary hypertension

Abstract

EDITORIAL FOCUSCaveolin-1: a critical regulator of pulmonary vascular architecture and nitric oxide bioavailability in pulmonary hypertensionStefan W. Ryter, and Augustine M. K. ChoiStefan W. Ryter, and Augustine M. K. ChoiPublished Online:01 May 2008https://doi.org/10.1152/ajplung.00074.2008This is the final version - click for previous versionMoreSectionsPDF (50 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations caveolae are 50- to 100-nm ω-shaped invaginations of the cell surface plasma membrane enriched in glycosphingolipids and cholesterol that occur in a variety of cell types including epithelial and endothelial cells, fibroblasts, smooth muscle cells, and adipocytes (1). These structures facilitate endocytosis of particles and participate in vesicular trafficking. Caveolin-1 (cav-1), a 21- to 24-kDa protein, is the major resident scaffolding protein constituent of caveolae (1). In addition to providing the structural integrity of caveolae, cav-1 exerts major regulatory functions on intracellular signaling pathways, in particular, those that originate at the plasma membrane. Cav-1 can form complexes with many signaling-associated proteins that reside in the caveolae, resulting in the modulation and usually inhibition of corresponding enzymatic activities. Among these are the endothelial (constitutive) nitric oxide synthase (eNOS; Ref. 5), heme oxygenase-1 (9), phosphatidylinositol 3-kinase, GTPases, estrogen receptors, the EGF and PDGF receptors, and others (1, 16).The profound involvement of cav-1 in cellular and tissue homeostasis is evident by the aberrant pulmonary and vascular phenotypes observed in cav-1 (cav-1−/−) animals, among which include hypercellularity in the lungs and heart (2, 4, 17–18). Although cav-1−/− mice are viable, they display a dramatically shortened life span and a distinct loss of caveolae structures (4, 13). Furthermore, cav-1−/− mice exhibit insulin resistance and hyperproliferation of adipose tissue (3). Significant cardiac defects were observed in cav-1−/− mice including increased right ventricular volume and hypertrophy, left ventricular wall thickening, loss of systolic function, and evidence of cardiac fibrosis (2, 4, 22). The lungs of cav-1−/− mice display a thickening of the parenchyma and alveolar septae resulting from bronchial and alveolar epithelial cell hyperproliferation (12, 17), evidence of endothelial cell proliferation (17), and pulmonary fibrosis (4).Despite systemic hypotension, cav-1−/− animals develop significant pulmonary hypertension and associated increases in pulmonary artery pressure and right ventricular hypertrophy as described in this issue of AJP-Lung by Maniatis et al. (11) and by others (4, 17, 23). Endothelial cell-specific reconstitution of cav-1 expression in cav-1−/− mice restored the pulmonary and vascular defects observed in these animals, as evident by the reversal of the pulmonary hypertension and cardiac hypertrophy (12). Alveolar hypercellularity was also partially compensated by cav-1 reconstitution, which inhibited the endothelial cell proliferation (12). These studies illustrate a major role for endothelium-expressed cav-1 in vascular homeostasis, although the importance of this molecule is not limited to endothelial cells.Extensive experimentation with cav-1−/− mice has revealed the critical role of cav-1 in the regulation of signaling processes. Cav-1−/− mice display increased eNOS expression in cardiac tissue, increased eNOS activity in aortic rings and responsiveness to acetylcholine-induced relaxation, increased systemic nitric oxide (NO) production, as well as increased NO release from vascular smooth muscle cells derived from these animals (2, 4, 17). The increased NO bioavailability for vascular processes has also been associated with increased nitrosative stress in these animals, as evidenced by increased nitrotyrosine formation in cardiac tissue (22). Further evidence of deregulated signaling pathways were evident by increased p42/44 MAPK (ERK1/2) activation in cardiac fibroblasts from cav-1−/− mice as well as increased Akt activation in lung vasculature, which promote the cardiac and pulmonary hypercellularity (2, 12).Cav-1 is known to reduce cell growth and influence apoptosis by inhibiting the activation of growth factor receptors and their downstream signaling pathways (1, 16). In addition, cav-1 negatively regulates smooth muscle cell proliferation (10, 15) and arrests mouse embryonic fibroblasts in the G0/G1 phase (6). Consistently, cav-1−/− mice show increased vascular smooth muscle cell proliferation and intimal hyperplasia in response to vascular injury (8), whereas stimulation of cav-1 expression decreases intimal hyperplasia (10). Cav-1 expression is increased in senescent cells and aged animals (14, 18). Furthermore, cav-1 has been identified as a candidate tumor-suppressor gene, such that mutations in the cav-1 gene have been associated with the growth of tumors (1). Wang et al. (19) have recently shown a critical antifibrotic potential of cav-1, such that cav-1 expression inhibited bleomycin-induced pulmonary fibrosis in mice. Furthermore, cav-1 expression was reduced in lung tissues and in primary pulmonary fibroblasts from idiopathic pulmonary fibrosis patients compared with controls (19). These reports, taken together, indicate that cav-1 plays important roles in the suppression of cellular proliferation, which can contribute to various vascular and pulmonary diseases.The current article in focus by Maniatis et al. (11) further demonstrates an antihypertensive and homeostatic function of cav-1 with respect to the pulmonary vascular architecture. In agreement with previous studies, cav-1−/− mice developed pulmonary hypertension as evidenced by increased vascular resistance, which the authors localized to the precapillary bed, with associated right ventricular hypertrophy. The development of pulmonary hypertension in cav-1−/− animals occurred despite the increased vascular NO production as the consequence of the loss of cav-1-dependent inhibition of eNOS activity. Chemical inhibition of NO production by acute treatment with NG-nitro-l-arginine methyl ester (l-NAME) increased pulmonary vascular resistance in both wild-type and cav-1−/− strains, although the effect was more pronounced in cav-1−/− mice. Furthermore, cav-1−/− were relatively resistant to vasoconstrictor-mediated responses relative to wild-type mice. These experiments are consistent with the measured twofold increase of plasma NO levels in cav-1−/− mice (11).Consistent with previous observations (4), cav-1−/− mice exhibited increased hypercellularity of the lung, thickening of the alveolar septae, and increased matrix deposition in the lung parenchyma with increases in α-smooth muscle actin and redistribution of collagen expression in lung parenchyma (11). Fluorescence imaging and electron microscopic studies revealed profound disruption of the pulmonary vasculature including remodeling and disorganization of precapillary vessels, decreased arterial density, and increased artery-filling defects in cav-1−/− mice. Additionally some evidence of perivascular fibrosis was observed (11).Based on these observations, Maniatis et al. (11) conclude that the increased NO production in cav-1−/− mice can provide a counter-regulatory mechanism that partially compensates for the increased vascular resistance observed in these animals. The hypertension in cav-1−/− mice was attributed primarily to morphological changes of the vasculature. Whereas NO, in addition to stimulating vasodilation, is known to inhibit smooth muscle cell proliferation, the increases in NO production in cav-1−/− mice apparently do not serve to inhibit the vascular remodeling that occurs with loss of cav-1 (11).The question remains as to whether the increased NO production contributes to disease pathogenesis in these animals, despite beneficial reversal of pulmonary artery resistance. This issue has been further addressed in the recent studies of Wunderlich et al. (21), which show that chronic application of l-NAME since the time of birth reduced pulmonary hypertension and vascular remodeling in cav-1−/− mice, which implicate a role for aberrant NO production in the early progression of vascular remodeling in these mice. It should be noted that eNOS-deficient mice, which are not viable, also display severe defects in pulmonary vascular development and pulmonary hypertension, thus illustrating potential contributory roles for both NO deficit and NO overproduction in the pathogenesis of this disease (7).In conclusion, the influence of cav-1 on vascular processes and vascular disease pathogenesis appears to be complex, potentially involving the modulation of signaling pathways that regulate cellular proliferation as well as vascular tone but are not necessarily restricted to modulation of NO bioavailability alone. Other potentially important sequelae of cav-1 deletion may include altered regulation of apoptosis and inflammation as suggested by other recent studies (20, 22). These additional functions of cav-1 may be relevant since pulmonary hypertension is associated with endothelial cell-specific apoptosis and considerable vascular inflammation. The studies of Maniatis et al. (11) provide an in-depth analysis of the pulmonary vascular defects that occur in cav-1−/− mice. From this work, it is evident that more research is required to understand the complex roles of cav-1 and its interrelationships with NO production in the context of pulmonary hypertension and other vascular disorders involving hyperproliferative responses.GRANTSThis work was supported, in part, by National Heart, Lung, and Blood Institute Grants R01-HL-079904 and P01-HL-70807 awarded to A. M. K. Choi.REFERENCES1 Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 84: 1341–1379, 2004.Link | ISI | Google Scholar2 Cohen AW, Park DS, Woodman SE, Williams TM, Chandra M, Shirani J, Pereira de Souza A, Kitsis RN, Russell RG, Weiss LM, Tang B, Jelicks LA, Factor SM, Shtutin V, Tanowitz HB, Lisanti MP. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am J Physiol Cell Physiol 284: C457–C474, 2003.Link | ISI | Google Scholar3 Cohen AW, Razani B, Wang XB, Combs TP, Williams TM, Scherer PE, Lisanti MP. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol 285: C222–C235, 2003.Link | ISI | Google Scholar4 Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, Kurzchalia TV. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293: 2449–2452, 2001.Crossref | PubMed | ISI | Google Scholar5 Feron O, Belhassen L, Kobzik L, Smith TW, Kelly RA, Michel T. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin-1 isoforms in cardiac myocytes and endothelial cells. J Biol Chem 271: 22810–22814, 1996.Crossref | PubMed | ISI | Google Scholar6 Galbiati F, Volonté D, Liu J, Capozza F, Frank PG, Zhu L, Pestell RG, Lisanti MP. Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrest via a p53/p21(WAF1/Cip1)-dependent mechanism. Mol Biol Cell 12: 2229–2244, 2001.Crossref | PubMed | ISI | Google Scholar7 Han RN, Babaei S, Robb M, Lee T, Ridsdale R, Ackerley C, Post M, Stewart DJ. Defective lung vascular development and fatal respiratory distress in endothelial NO synthase-deficient mice: a model of alveolar capillary dysplasia? Circ Res 94: 1115–1123, 2004.Crossref | PubMed | ISI | Google Scholar8 Hassan GS, Jasmin JF, Schubert W, Frank PG, Lisanti MP. Caveolin-1 deficiency stimulates neointima formation during vascular injury. Biochemistry 43: 8312–8321, 2004.Crossref | PubMed | ISI | Google Scholar9 Kim HP, Wang X, Galbiati F, Ryter SW, Choi AM. Caveolae compartmentalization of heme oxygenase-1 in endothelial cells. FASEB J 18: 1080–1099, 2004.Crossref | PubMed | ISI | Google Scholar10 Kim HP, Wang X, Nakao A, Kim SI, Murase N, Choi ME, Ryter SW, Choi AM. Caveolin-1 expression by means of p38beta mitogen-activated protein kinase mediates the antiproliferative effect of carbon monoxide. Proc Natl Acad Sci USA 102: 11319–11324, 2005.Crossref | PubMed | ISI | Google Scholar11 Maniatis NA, Shinin V, Schraufnagel DE, Okada S, Vogel SM, Malik AB, Minshall RD. Increased pulmonary vascular resistance and defective pulmonary artery filling in caveolin-1−/− mice. Am J Physiol Lung Cell Mol Physiol (January 11, 2008). doi:10.1152/ajplung.00079.2007.Link | ISI | Google Scholar12 Murata T, Lin MI, Huang Y, Yu J, Bauer PM, Giordano FJ, Sessa WC. Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice. J Exp Med 204: 2373–2382, 2007.Crossref | PubMed | ISI | Google Scholar13 Park DS, Cohen AW, Frank PG, Razani B, Lee H, Williams TM, Chandra M, Shirani J, De Souza AP, Tang B, Jelicks LA, Factor SM, Weiss LM, Tanowitz HB, Lisanti MP. Caveolin-1 null (−/−) mice show dramatic reductions in life span. Biochemistry 42: 15124–15131, 2003.Crossref | PubMed | ISI | Google Scholar14 Park WY, Park JS, Cho KA, Kim DI, Ko YG, Seo JS, Park SC. Up-regulation of caveolin attenuates epidermal growth factor signaling in senescent cells. J Biol Chem 275: 20847–20852, 2000.Crossref | PubMed | ISI | Google Scholar15 Peterson TE, Guicciardi ME, Gulati R, Kleppe LS, Mueske CS, Mookadam M, Sowa G, Gores GJ, Sessa WC, Simari RD. Caveolin-1 can regulate vascular smooth muscle cell fate by switching platelet-derived growth factor signaling from a proliferative to an apoptotic pathway. Arterioscler Thromb Vasc Biol 23: 1521–1527, 2003.Crossref | PubMed | ISI | Google Scholar16 Pike LJ. Growth factor receptors, lipid rafts and caveolae: an evolving story. Biochim Biophys Acta 1746: 260–273, 2005.Crossref | PubMed | ISI | Google Scholar17 Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H Jr, Kneitz B, Lagaud G, Christ GJ, Edelmann W, Lisanti MP. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 276: 38121–38138, 2001.Crossref | PubMed | ISI | Google Scholar18 Volonte D, Zhang K, Lisanti MP, Galbiati F. Expression of caveolin-1 induces premature cellular senescence in primary cultures of murine fibroblasts. Mol Biol Cell 13: 2502–2517, 2002.Crossref | PubMed | ISI | Google Scholar19 Wang XM, Zhang Y, Kim HP, Zhou Z, Feghali-Bostwick CA, Liu F, Ifedigbo E, Xu X, Oury TD, Kaminski N, Choi AM. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med 203: 2895–2906, 2006.Crossref | PubMed | ISI | Google Scholar20 Wang XM, Kim HP, Song R, Choi AM. Caveolin-1 confers antiinflammatory effects in murine macrophages via the MKK3/p38 MAPK pathway. Am J Respir Cell Mol Biol 34: 434–442, 2006.Crossref | PubMed | ISI | Google Scholar21 Wunderlich C, Schmeisser A, Heerwagen C, Ebner B, Schober K, Braun-Dullaeus RC, Schwencke C, Kasper M, Morawietz H, Strasser RH. Chronic NOS inhibition prevents adverse lung remodeling and pulmonary arterial hypertension in caveolin-1 knockout mice. Pulm Pharmacol Ther. In press.Google Scholar22 Wunderlich C, Schober K, Lange SA, Drab M, Braun-Dullaeus RC, Kasper M, Schwencke C, Schmeisser A, Strasser RH. Disruption of caveolin-1 leads to enhanced nitrosative stress and severe systolic and diastolic heart failure. Biochem Biophys Res Commun 340: 702–708, 2006.Crossref | PubMed | ISI | Google Scholar23 Zhao YY, Liu Y, Stan RV, Fan L, Gu Y, Dalton N, Chu PH, Peterson K, Ross J Jr, Chien KR. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA 99: 11375–11380, 2002.Crossref | PubMed | ISI | Google ScholarAUTHOR NOTESAddress for reprint requests and other correspondence: A. M. K. Choi, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA 02115 (e-mail: [email protected]) Download PDF Previous Back to Top Next FiguresReferencesRelatedInformation Cited ByImbalance of Caveolin-1 and eNOS Expression in the Pulmonary Vasculature of Experimental Diaphragmatic Hernia30 July 2014 | Birth Defects Research Part B: Developmental and Reproductive Toxicology, Vol. 101, No. 4The role of caveolae in the pathophysiology of lung diseases5 December 2013 | Expert Review of Respiratory Medicine, Vol. 8, No. 1The regulation of endothelial nitric oxide synthase by caveolin: a paradigm validated in vivo and shared by the ‘endothelium-derived hyperpolarizing factor’26 March 2010 | Pflügers Archiv - European Journal of Physiology, Vol. 459, No. 6Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertensionJournal of Hypertension, Vol. 28, No. 2 More from this issue > Volume 294Issue 5May 2008Pages L862-L864 Copyright & PermissionsCopyright © 2008 the American Physiological Societyhttps://doi.org/10.1152/ajplung.00074.2008PubMed18296499History Published online 1 May 2008 Published in print 1 May 2008 Metrics